$56.63
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Should You Be Bullish on Forte Biosciences (FBRX)?
Barclays Initiates Forte Biosciences at Overweight With $74 Price Target
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
Overview
52-week range
$9.10
$36
100% of range
Avg surprise (last 2)
-16.6%
Avg reaction (last 2)
+5.6%
100% positive
Latest IV / EM
184%
EM ±42.0% · $55 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-1.24 | — | — | +9.5% | +8.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.99 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.96 | $-1.21 | +20.7% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-1.37 | $-0.89 | -53.9% | — | +3.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-4.54 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-6.78 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-4.03 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-6.57 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.42 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$1.08 | -$0.96 | -12.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-22M | — | $-18M | $-12M | $-16M | — | $-9M | $-13M |
| Net income | $-22M | — | $-18M | $-11M | $-16M | — | $-8M | $-13M |
| EPS (diluted) | $-1.24 | — | $-0.99 | $-0.96 | $-1.37 | — | $-4.54 | $-6.78 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $58M | $77M | $93M | $106M | $46M | $22M | $16M | $24M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $65M | $81M | $95M | $108M | $47M | $61M | $18M | $26M |
| Total assets | $67M | $83M | $97M | $108M | $47M | $62M | $18M | $26M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $25M | $22M | — | — | — | — | — | — |
| Total equity | $42M | $61M | $84M | $99M | $38M | $52M | $9M | $17M |